Combined PKCiota and mTOR Inhibition for Treatment of Advanced Squamous Lung Cancer.

Trial Profile

Combined PKCiota and mTOR Inhibition for Treatment of Advanced Squamous Lung Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2017

At a glance

  • Drugs Sirolimus (Primary) ; Sodium aurothiomalate (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 14 Dec 2012 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 18 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top